Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis
Teppei Matsumoto(Hirosaki University), Chikara Οhyama(Hirosaki University), Shingo Hatakeyama(Hirosaki University), Tomonori Habuchi(Akita University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Norihiko Tsuchiya(Yamagata University), Takuma Narita(Hirosaki University), Shintaro Narita(Akita University), Shinichi Yamashita, Takuya Koie(Hirosaki University), Takamitsu Inoue(International University of Health and Welfare), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Yoichi Arai(Japan Atomic Energy Agency), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Teppei Ookubo(Tohoku University)
Cited by 14
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253